Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
Salvatore Siena(University of Milan), Takayuki Yoshino(University of Tsukuba), Hisato Kawakami(Tohoku University), Zev A. Wainberg(University of California, Los Angeles), Ki Y. Chung(Prisma Health), Andrea Sartore‐Bianchi(University of Milan), Elena Élez(Vall d'Hebron Hospital Universitari), Toshiki Masuishi(Aichi Cancer Center), Kanwal Raghav(The University of Texas MD Anderson Cancer Center), Emarjola Bako(BVI (United States)), Javad Shahidi(Daiichi Sankyo (United States)), Yoshito Komatsu(Hokkaido University Hospital), Fotios Loupakis(Azienda Ospedaliera Universitaria Pisana), Taito Esaki(National Hospital Organization Kyushu Cancer Center), Fortunato Ciardiello(University of Campania "Luigi Vanvitelli"), Axel Grothey(Campbell Clinic), Marwan Fakih(City of Hope), Maria Di Bartolomeo(Fondazione IRCCS Istituto Nazionale dei Tumori), Tomohiro Nishina(Shikoku Cancer Center), Kensei Yamaguchi(Japanese Foundation For Cancer Research), Javier Rodríguez(Clinica Universidad de Navarra), Yasuyuki Okuda(Daiichi-Sankyo (Japan)), Eriko Yamamoto(Daiichi-Sankyo (Japan)), Kapil Saxena(Daiichi Sankyo (United States))
Cited by 411
Related Papers
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2019|2k